US 11,717,526 B2
Pharmaceutical compositions comprising a ryanodine receptor modulator and uses thereof
Eugene E. Marcantonio, Tenafly, NJ (US); Mette Uhre Anby, Frederiksberg (DK); and Jérôme Binet, Saint Denis en Val (FR)
Assigned to ARMGO Pharma, Inc., Ardsley, NY (US)
Filed by ARMGO Pharma, Inc., Ardsley, NY (US)
Filed on May 19, 2022, as Appl. No. 17/748,886.
Claims priority of provisional application 63/191,142, filed on May 20, 2021.
Prior Publication US 2022/0387442 A1, Dec. 8, 2022
Int. Cl. A61K 31/554 (2006.01); A61P 21/00 (2006.01); A61K 9/28 (2006.01)
CPC A61K 31/554 (2013.01) [A61K 9/2866 (2013.01); A61K 9/2886 (2013.01); A61P 21/00 (2018.01)] 25 Claims
 
1. A pharmaceutical composition comprising in a unit dosage form 4-[(7-methoxy-2,3-dihydro-1,4-benzothiazepin-4(5H)yl)methyl]benzoic acid or a pharmaceutically-acceptable salt thereof, and a pharmaceutically-acceptable excipient, wherein the unit dosage form is a modified release dosage form, wherein when administered to a subject, the pharmaceutical composition provides to the subject a maximum plasma concentration of 4-[(7-methoxy-2,3-dihydro-1,4-benzothiazepin-4(5H)yl)methyl]benzoic acid or the pharmaceutically-acceptable salt thereof or a pharmaceutically-acceptable ion thereof at a time between about 2 to about 6 hours after administration, and an in-vivo mean terminal half-life of 4-[(7-methoxy-2,3-dihydro-1,4-benzothiazepin-4(5H)yl)methyl]benzoic acid or the pharmaceutically-acceptable salt thereof or a pharmaceutically-acceptable ion thereof of about 14 to about 21 hours after administration.